Cullinan Oncology Statistics
Share Statistics
Cullinan Oncology has 59.01M
shares outstanding. The number of shares has increased by 1.52%
in one year.
| Shares Outstanding | 59.01M |
| Shares Change (YoY) | 1.52% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 389 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 7.48M, so 12.67% of the outstanding
shares have been sold short.
| Short Interest | 7.48M |
| Short % of Shares Out | 12.67% |
| Short % of Float | 14.66% |
| Short Ratio (days to cover) | 17.61 |
Valuation Ratios
The PE ratio is -3.91 and the forward
PE ratio is -2.58.
Cullinan Oncology's PEG ratio is
0.25.
| PE Ratio | -3.91 |
| Forward PE | -2.58 |
| PS Ratio | 0 |
| Forward PS | 3.4 |
| PB Ratio | 1.11 |
| P/FCF Ratio | -4.51 |
| PEG Ratio | 0.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cullinan Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.53,
with a Debt / Equity ratio of 0.
| Current Ratio | 13.53 |
| Quick Ratio | 13.53 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,507,954.95 |
| Employee Count | 111 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 117K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -66% in the
last 52 weeks. The beta is -0.07, so Cullinan Oncology's
price volatility has been lower than the market average.
| Beta | -0.07 |
| 52-Week Price Change | -66% |
| 50-Day Moving Average | 7.95 |
| 200-Day Moving Average | 12.26 |
| Relative Strength Index (RSI) | 49.3 |
| Average Volume (20 Days) | 466,840 |
Income Statement
| Revenue | n/a |
| Gross Profit | -306K |
| Operating Income | -196.92M |
| Net Income | -167.38M |
| EBITDA | -167.15M |
| EBIT | -167.46M |
| Earnings Per Share (EPS) | -3.11 |
Full Income StatementBalance Sheet
The company has 83M in cash and 2.15M in
debt, giving a net cash position of 80.85M.
| Cash & Cash Equivalents | 83M |
| Total Debt | 2.15M |
| Net Cash | 80.85M |
| Retained Earnings | -368.24M |
| Total Assets | 579.68M |
| Working Capital | 290.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -145.3M
and capital expenditures 0, giving a free cash flow of -145.3M.
| Operating Cash Flow | -145.3M |
| Capital Expenditures | n/a |
| Free Cash Flow | -145.3M |
| FCF Per Share | -2.7 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
